|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 April 2001, Vol. 97, No. 7, pp. 2053-2058
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Identification of polymorphisms in the promoter and the 3' region
of the TAFI gene: evidence that plasma TAFI antigen levels
are strongly genetically controlled
Mireille Henry,
Hélène Aubert,
Pierre E. Morange,
Isabelle Nanni,
Marie-Christine Alessi,
Laurence Tiret, and
Irène Juhan-Vague
From the Laboratoire d'Hématologie, INSERM EPI
99-36, Marseilles, and INSERM U525, Paris, France.
Thrombin-activable fibrinolysis inhibitor (TAFI) is a recently
described carboxypeptidase that is potentially involved in the
regulation of fibrinolysis by decreasing plasminogen binding to the
fibrin surface. This role makes the TAFI gene a good
candidate in atherothrombotic diseases. The great interindividual
variability of plasma TAFI antigen levels is poorly explained by
lifestyle characteristics, thus suggesting its genetic determination.
To test this hypothesis, the promoter and the 3'-untranslated region of
the TAFI gene were screened for polymorphisms, and their
contribution to the variability of plasma TAFI antigen levels was
evaluated. Seven new polymorphisms are described, 5 in the promoter
(C-2599G,  2345 2G/1G, A-1690G, G-1102T, and G-438A) and 2 in the
3'UTR (C+1542G and T+1583A). All these polymorphisms were in strong linkage disequilibrium with each other and with the previously described Ala147Thr polymorphism. They generated 4 main haplotypes, accounting for 80% of all observed haplotypes. In univariate analyses, all polymorphisms were associated with plasma TAFI Ag levels and, individually, contributed to a large fraction of plasma TAFI Ag levels,
ranging from 20% to 52%. In a stepwise regression analysis including
all polymorphisms, several combinations remained significantly and
independently associated with plasma TAFI Ag levels: C+1542G associated
with Ala147Thr, T+1583A, or 2345 2G/1G explaining 61.6%, 60.2%, and
58.1% of the variance, respectively. These findings clearly
demonstrate that circulating levels of TAFI are strongly determined by
polymorphic variations in the promoter and the 3'UTR of the
TAFI gene.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letter in Blood Online:
-
A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels
- Geert-Jan Brouwers, Hans L. Vos, Frank W. G. Leebeek, Saskia Bulk, Mark Schneider, Michael Boffa, Marlys Koschinsky, Nico H. van Tilburg, Michael E. Nesheim, Rogier M. Bertina, and Encarnación B. Gómez García
Blood 2001 98: 1992-1993.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. E. Meltzer, C. J.M. Doggen, P. G. de Groot, J. C.M. Meijers, F. R. Rosendaal, and T. Lisman
Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men
Haematologica,
June 1, 2009;
94(6):
811 - 818.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Boffa, D. Maret, J. D. Hamill, N. Bastajian, P. Crainich, N. S. Jenny, Z. Tang, E. M. Macy, R. P. Tracy, R. F. Franco, et al.
Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis
Blood,
January 1, 2008;
111(1):
183 - 189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sucker, G. R. Hetzel, F. Farokhzad, F. Dahhan, M. Schmitz, C. Kurschat, B. Grabensee, B. Maruhn-Debowski, R. Zotz, and R. Scharf
Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study
Nephrol. Dial. Transplant.,
May 1, 2007;
22(5):
1347 - 1350.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ladenvall, A. Gils, K. Jood, C. Blomstrand, P. J. Declerck, and C. Jern
Thrombin Activatable Fibrinolysis Inhibitor Activation Peptide Shows Association With All Major Subtypes of Ischemic Stroke and With TAFI Gene Variation
Arterioscler. Thromb. Vasc. Biol.,
April 1, 2007;
27(4):
955 - 962.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. T. Morozowich, B. S. Donahue, and I. J. Welsby
Genetics of coagulation: considerations for cardiac surgery.
Seminars in Cardiothoracic and Vascular Anesthesia,
December 1, 2006;
10(4):
297 - 313.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Frere, D.-A. Tregouet, P.-E. Morange, N. Saut, D. Kouassi, I. Juhan-Vague, L. Tiret, and M.-C. Alessi
Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study
Blood,
September 1, 2006;
108(5):
1562 - 1568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Willemse and D. F. Hendriks
Measurement of Procarboxypeptidase U (TAFI) in Human Plasma: A Laboratory Challenge
Clin. Chem.,
January 1, 2006;
52(1):
30 - 36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Aso, S. Wakabayashi, R. Yamamoto, R. Matsutomo, K. Takebayashi, and T. Inukai
Metabolic Syndrome Accompanied by Hypercholesterolemia Is Strongly Associated With Proinflammatory State and Impairment of Fibrinolysis in Patients With Type 2 Diabetes: Synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor
Diabetes Care,
September 1, 2005;
28(9):
2211 - 2216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Voetsch and J. Loscalzo
Genetic Determinants of Arterial Thrombosis
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2004;
24(2):
216 - 229.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L. O. Mosnier, P. Buijtenhuijs, P. F. Marx, J. C. M. Meijers, and B. N. Bouma
Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets
Blood,
June 15, 2003;
101(12):
4844 - 4846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Gils, M.-C. Alessi, E. Brouwers, M. Peeters, P. Marx, J. Leurs, B. Bouma, D. Hendriks, I. Juhan-Vague, and P. J. Declerck
Development of a Genotype 325-Specific proCPU/TAFI ELISA
Arterioscler. Thromb. Vasc. Biol.,
June 1, 2003;
23(6):
1122 - 1127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Boffa, J. D. Hamill, N. Bastajian, R. Dillon, M. E. Nesheim, and M. L. Koschinsky
A Role for CCAAT/Enhancer-binding Protein in Hepatic Expression of Thrombin-activable Fibrinolysis Inhibitor
J. Biol. Chem.,
July 5, 2002;
277(28):
25329 - 25336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Juhan-Vague, P.E. Morange, H. Aubert, M. Henry, M.F. Aillaud, M.C. Alessi, A. Samnegard, E. Hawe, J. Yudkin, M. Margaglione, et al.
Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe
Arterioscler. Thromb. Vasc. Biol.,
May 1, 2002;
22(5):
867 - 873.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Morange, M. Henry, C. Frere, and I. Juhan-Vague
Thr325Ile polymorphism of the TAFI gene does not influence the risk of myocardial infarction
Blood,
March 1, 2002;
99(5):
1878 - 1878.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G.-J. Brouwers, H. L. Vos, F. W. G. Leebeek, S. Bulk, M. Schneider, M. Boffa, M. Koschinsky, N. H. van Tilburg, M. E. Nesheim, R. M. Bertina, et al.
A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels
Blood,
September 15, 2001;
98(6):
1992 - 1993.
[Full Text]
[PDF]
|
|
|
|
|
